Free tool
FAERS Monitor: Orbactiv
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206334 or its brand name (Orbactiv, Oritavancin Diphosphate). Reports on generic versions are filed under their own applications.
Reports
920
Serious
352
38% of reports
Hospitalization
172
Death reported
32
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use175
- pruritus165
- urticaria105
- chills90
- rash86
- back pain83
- dyspnoea81
- nausea68
- infusion related reaction62
- erythema58
- chest pain56
- drug ineffective49
- flushing41
- vomiting41
- headache39
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 47 |
| 2016 | 159 |
| 2017 | 182 |
| 2018 | 141 |
| 2019 | 82 |
| 2020 | 73 |
| 2021 | 41 |
| 2022 | 67 |
| 2023 | 38 |
| 2024 | 36 |
| 2025 | 30 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,239 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 62 | 21.4 | 16.8 | 1,188 |
| chillsSignal | 90 | 17.6 | 14.4 | 1,396 |
| urticariaSignal | 105 | 14.3 | 12.0 | 1,299 |
| pruritusSignal | 165 | 9.8 | 8.6 | 1,322 |
| flushingSignal | 41 | 9.2 | 6.8 | 294 |
| back painSignal | 83 | 8.2 | 6.7 | 521 |
| chest painSignal | 56 | 6.9 | 5.4 | 280 |
| erythemaSignal | 58 | 6.5 | 5.0 | 264 |
| off label useSignal | 175 | 4.6 | 4.0 | 505 |
| rashSignal | 86 | 4.5 | 3.7 | 236 |
| dyspnoeaSignal | 81 | 3.3 | 2.7 | 129 |
| vomiting | 41 | 2.0 | 1.5 | 20 |
| nausea | 68 | 2.0 | 1.6 | 32 |
| headache | 39 | 1.4 | 1.0 | 5 |
| drug ineffective | 49 | 0.8 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.